NextPoint Therapeutics
Cambridge, United States· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $122.5M
Overview
A biotech developing first-in-class immuno-oncology drugs targeting the novel HHLA2 checkpoint pathway.
OncologyImmunology
Technology Platform
A proprietary platform focused on the biology and therapeutic modulation of the HHLA2 immune checkpoint pathway and its receptors.
Funding History
2Total raised:$122.5M
Series B$42.5M
Series B$80M
Opportunities
Validating HHLA2 could unlock a major new checkpoint inhibitor class for patients unresponsive to PD-1/PD-L1 therapies.
Risk Factors
The novel biology carries inherent clinical risk, and failure to show efficacy in first-in-human trials would be a major setback.
Competitive Landscape
Operates in the highly competitive immuno-oncology space but has first-mover advantage on the novel HHLA2 target, with limited direct competition currently.